8-K: Viking Therapeutics Announces Positive Q1 2025 Financial Results and Provides Corporate Update, Including Progress on VK2735 Obesity Program

Viking Therapeutics reports a strong cash position of $852 million and progress in its VK2735 obesity program, with Phase 3 trials expected to begin in Q2 2025 and Phase 2 oral dosing trial data anticipated in 2H25.

Summary

• Viking Therapeutics announced its financial results for the first quarter ended March 31, 2025, and provided a corporate update.
• Phase 3 trials for subcutaneous VK2735 in obesity are expected to begin in the second quarter of 2025.
• The Phase 2 VENTURE-Oral Dosing trial in obesity is fully enrolled, with data expected in the second half of 2025.
• Viking has entered into a broad manufacturing agreement with CordenPharma to support the future commercialization of VK2735.
• The company reported a strong quarter-end cash position of $852 million.
• Research and development expenses were $41.4 million for the three months ended March 31, 2025, compared to $24.1 million for the same period in 2024.
• General and administrative expenses were $14.1 million for the three months ended March 31, 2025, compared to $10.0 million for the same period in 2024.
• For the three months ended March 31, 2025, Viking reported a net loss of $45.6 million, or $0.41 per share, compared to a net loss of $27.4 million, or $0.26 per share, in the corresponding period in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting clinical trial progress, a strong cash position, and a manufacturing agreement. However, increased expenses and a net loss temper the overall sentiment.

Positives

• Viking has a strong cash position of $852 million, providing financial flexibility.
• Phase 3 trials for subcutaneous VK2735 are on track to begin in Q2 2025.
• The Phase 2 VENTURE-Oral Dosing trial is fully enrolled, indicating strong interest in the oral formulation of VK2735.
• The manufacturing agreement with CordenPharma secures large-scale supply of VK2735 API and fill/finish capacity.
• The company is advancing its novel amylin agonist program, with an IND filing expected in 2H25.
• The VENTURE trial demonstrated statistically significant reductions in body weight with VK2735, up to 14.7% after 13 weeks.

Negatives

• Viking reported a net loss of $45.6 million, or $0.41 per share, for the three months ended March 31, 2025, compared to a net loss of $27.4 million, or $0.26 per share, in the corresponding period in 2024.
• Research and development expenses increased to $41.4 million for the three months ended March 31, 2025, compared to $24.1 million for the same period in 2024.
• General and administrative expenses increased to $14.1 million for the three months ended March 31, 2025, compared to $10.0 million for the same period in 2024.
• Cash, cash equivalents and short-term investments decreased from $903 million as of December 31, 2024 to $852 million as of March 31, 2025.

Risks

• The success, cost, and timing of Viking's product candidate development activities and clinical trials are subject to risks and uncertainties.
• Prior clinical and preclinical results may not be replicated in future trials.
• Regulatory requirements could pose risks to the development and commercialization of Viking's product candidates.
• The company's cash resources may be depleted faster than expected, requiring additional financing.

Future Outlook

Viking expects to initiate Phase 3 trials evaluating subcutaneous VK2735 in obesity in the second quarter of 2025 and anticipates reporting data from the Phase 2 VENTURE-Oral Dosing trial in the second half of 2025. The company also plans to file an IND for its dual amylin and calcitonin receptor agonist (DACRA) program in the second half of 2025.

Management Comments

• In the first quarter of 2025 Viking continued to build on the strong momentum achieved in 2024, stated Brian Lian, Ph.D., chief executive officer of Viking.
• Throughout the first quarter we continued to ramp up activities in support of the initiation of Phase 3 trials with the subcutaneous formulation of VK2735, which are on track to begin later this quarter.
• We believe the trials rapid enrollment reflects continued enthusiasm for our VK2735 programs among investigators and study subjects.
• We look forward to reporting the results of this study in the second half of the year.
• Finally, we completed the quarter with a strong balance sheet and over $850 million in cash, which allows us to continue to efficiently develop our pipeline programs.

Industry Context

Viking's focus on developing novel therapies for metabolic and endocrine disorders, particularly obesity, aligns with the growing market demand for effective weight management solutions. The progress of VK2735, a dual GLP-1/GIP receptor agonist, positions Viking to potentially compete with established players in the obesity treatment space.

Comparison to Industry Standards

• The reported 14.7% weight loss in the Phase 2 VENTURE study of VK2735 is competitive with other GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro).
• The development of both subcutaneous and oral formulations of VK2735 mirrors the strategies of companies like Novo Nordisk and Eli Lilly, which offer both injectable and oral options for their diabetes and obesity drugs.
• The manufacturing agreement with CordenPharma is similar to other biopharmaceutical companies securing manufacturing capacity to support commercialization of their products.

Stakeholder Impact

• Shareholders may be positively impacted by the progress of VK2735 and the company's strong financial position.
• Employees may benefit from the company's growth and expansion of its clinical programs.
• Patients may have access to new and effective treatments for obesity and other metabolic disorders.
• The manufacturing agreement with CordenPharma could positively impact the supplier relationship.

Next Steps

• Initiate Phase 3 trials for subcutaneous VK2735 in obesity in Q2 2025.
• Report data from the Phase 2 VENTURE-Oral Dosing trial in 2H25.
• File an IND for the dual amylin and calcitonin receptor agonist (DACRA) program in 2H25.
• Participate in upcoming investor events.

Key Dates

Keywords

VK2735, Obesity, GLP-1, GIP, Clinical Trials, Metabolic Disorders, Viking Therapeutics, Financial Results